

Supplemental Data Table 1: Blood Pressure, Laboratory Tests, and Metabolic Indices Monitored During Study Therapy

Variable	Low Testosterone			High Testosterone			ANOVA P-value
	GH Placebo (n=19) Group A	GH 3ug (n=19) Group B	GH 5ug (n=20) Group C	GH Placebo (n=20) Group D	GH 3ug (n=17) Group E	GH 5ug (n=17) Group F	
Systolic Blood Pressure <i>mmHg</i>^a							
Baseline	121±15	117±13	113±13	118±15	119±13	116±12	p=0.57
Week 16	134±18	129±18	124±21	131±14	129±23	131±13	p=0.66
Change at Week 16	13±16 13 (-26, 42) ^b	13±17 13 (-36, 38)	12±18 13 (-18, 39)	15±9 16 (-3, 30)	9±14 10 (-14, 34)	15±13 17 (-7, 37)	
Paired t-test	0.001	0.01	0.01	<0.0001	0.02	0.0003	
Diastolic Blood Pressure <i>mmHg</i>^a							
Baseline	70±8	68±7	66±7	68±5	68±6	69±9	p=0.57
Week 16	77±8	76±8	74±8	76±7	75±10	79±11	p=0.64
Change at Week 16	7±9 7 (-11, 19)	7±8 8 (-7, 21)	8±9 8 (-8, 23)	8±5 8 (-3, 16)	7±8 6 (-6, 22)	10±10 8 (-12, 27)	
Paired t-test	0.004	0.001	0.0002	<0.0001	0.003	0.001	

a. For blood pressure, the baseline value was taken from the minimum value among pre-entry 1, 2, 3, and baseline values. The value for week 16 was taken from minimum value among three measures at that visit.

b. Median (range)

Supplemental Data Table 1: Blood Pressure, Laboratory Tests, and Metabolic Indices Monitored During Study Therapy (continued)

Variable	Low Testosterone			High Testosterone			ANOVA P-value
	GH Placebo (n=19) Group A	GH 3ug (n=19) Group B	GH 5ug (n=20) Group C	GH Placebo (n=20) Group D	GH 3ug (n=17) Group E	GH 5ug (n=17) Group F	
Hematocrit %							
Baseline	43±3	43±1	44±2	42±2	43±2	43±2	p=0.34
Week 16	45±3	43±2	45±4	44±3	46±3	45±3	p=0.52
Change at Week 16	2±3 3 (-4, 5)	1±3 0 (-5, 6)	1±3 1 (-3, 7)	3±4 3 (-4, 12)	3±3 4 (-3, 7)	3±3 3 (-5, 8)	
Paired t-test	0.01†	0.33	0.14	0.003	0.001	0.004	
Prostate Specific Antigen (PSA) ng/mL							
Baseline	1.8±1.0	1.2±0.7	1.5±1.0	1.4±0.8	1.7±0.7	1.4±0.9	p=0.45
Week 16	1.9±1.2	1.4±0.8	1.6±1.1	1.6±1.2	2.0±1.2	1.8±1.1	p=0.68
Change at Week 16	0.1±0.9 0.1 (-3.0, 1.1)	0.1±0.3 0.1 (-0.4, 0.8)	0.1±0.8 0.1 (-1.8, 1.4)	0.3±0.9 0.2 (-1.1, 3.4)	0.3±1.1 0.0 (-1.0, 3.3)	0.4±0.5 0.4 (-0.2, 1.6)	
Paired t-test	0.15†	0.11†	0.53	0.12†	0.59†	0.003	

† When assumption of normality was violated, p-value was from Signed test.

Supplemental Data Table 1: Blood Pressure, Laboratory Tests, and Metabolic Indices Monitored During Study Therapy (continued)

Variable	Low Testosterone			High Testosterone			ANOVA P-value
	GH Placebo (n=19) Group A	GH 3ug (n=19) Group B	GH 5ug (n=20) Group C	GH Placebo (n=20) Group D	GH 3ug (n=17) Group E	GH 5ug (n=17) Group F	
Alanine Aminotransferase U/L							
Baseline	29±8	30±6	31±10	29±10	31±12	32±10	p=0.95
Week 16	29±7	34±11	30±9	30±13	30±13	30±8	p=0.80
Change at Week 16	0±6 0 (-14, 13)	4±10 1 (-7, 28)	-1±6 -1 (-14, 15)	0±16 -3 (-24, 49)	-1±13 -1 (-38, 30)	-1±7 -1 (-16, 14)	
Paired t-test	0.91	0.41†	0.57	0.40†	0.83†	0.45	
Fasting Blood Sugar mg/dL							
Baseline	92±9	92±8	93±0	88±8	92±18	93±9	p=0.78
Week 16	93±15	98±10	93±15	93±10	95±14	96±10	p=0.80
Change at Week 16	1±10 1 (-21, 18)	5±10 3 (-7, 26)	0±13 3 (-33, 16)	5±8 4 (-8, 19)	4±11 6 (-21, 20)	3±9 3 (-12,23)	
Paired t-test	0.59	0.10†	0.91	0.01	0.15	0.19	

† When assumption of normality was violated, p-value was from Signed test.

Supplemental Data Table 1: Blood Pressure, Laboratory Tests, and Metabolic Indices Monitored During Study Therapy (continued)

Variable	Low Testosterone			High Testosterone			ANOVA P-value
	GH Placebo (n=19) Group A	GH 3ug (n=19) Group B	GH 5ug (n=20) Group C	GH Placebo (n=20) Group D	GH 3ug (n=17) Group E	GH 5ug (n=17) Group F	
HOMA-IR^a							
Baseline	1.4±0.8	1.6±1.5	1.9±1.0	1.4±0.6	1.5±1.2	1.7±0.9	p=0.53
Week 16	1.7±1.3	1.8±1.5	2.4±1.3	2.5±3.8	1.9±1.2	2.1±2.0	p=0.71
Change at Week 16	0.3±0.8 -0.1 (-0.6, 2.4)	0.3±1.9 0.3 (-5.1, 5.6)	1.0±2.6 0.7 (-1.9, 11.0)	1.1±3.4 0.3 (-0.6, 15.4)	0.3±1.2 0.2 (-1.7, 2.9)	0.3±1.7 0.1 (-1.6, 5.0)	
Paired t-test	0.22	0.06†	0.09	0.03†	0.32	0.41	
QUICKI							
Baseline	1.4±0.8	1.6±1.5	1.9±1.0	1.4±0.6	1.5±1.2	1.7±0.9	p=0.55
Week 16	1.7±1.3	1.8±1.5	2.4±1.3	2.5±3.8	1.9±1.2	2.1±2.0	p=0.80
Change at Week 16	0.000±0.010 0.002 (-0.026,0.021)	-0.004±0.015 -0.007 (-0.037,0.026)	-0.004±0.016 -0.007 (-0.028,0.027)	-0.007±0.013 -0.008 (-0.038,0.013)	-0.006±0.016 -0.006 (-0.040,0.018)	0.001±0.015 -0.002 (-0.033,0.025)	
Paired t-test	0.96	0.24	0.28	0.05	0.16	0.88	

a. HOMA-IR = $[(I_f) \times (G_f)]/22.5$, where (I_f) is the fasting insulin level (μ U/ml) and (G_f) is the fasting glucose level (mmol/L)

b. QUICKI = $1/[\log(I_f) + \log(G_f)]$, where (I_f) is the fasting insulin level (uU/ml) and (G_f) is the fasting glucose level (mg/dL)

† When assumption of normality was violated, p-value was from Signed test.

Supplemental Data Table 1: Blood Pressure, Laboratory Tests, and Metabolic Indices Monitored During Study Therapy (continued)

Variable	Low Testosterone			High Testosterone			ANOVA P-value
	GH Placebo (n=19) Group A	GH 3ug (n=19) Group B	GH 5ug (n=20) Group C	GH Placebo (n=20) Group D	GH 3ug (n=17) Group E	GH 5ug (n=17) Group F	
Triglyceride <i>mg/dL</i>							
Baseline	126±64	112±40	142±69	125±63	114±50	130±73	p=0.72
Week 16	111±50	100±43	131±56	105±42	101±33	90±37	p=0.13
Change at Week 16	-15±68 -8 (-190, 150)	-12±42 -13 (-66, 128)	-11±54 -13 (-118, 92)	-20±42 -12 (-125, 29)	-13±56 -3 (-123, 72)	-40±77 -25 (-276, 74)	
Paired t-test	0.35	0.03†	0.39	0.06†	0.36	0.003†	
Total Cholesterol <i>mg/dL</i>							
Baseline	172±23	174±28	170±32	179±28	179±26	174±32	p=0.91
Week 16	183±34	183±28	169±26	184±35	178±25	161±24	p=0.10
Change at Week 16	11±29 14 (-63, 45)	10±20 7 (-28, 47)	-1±25 -2 (-63, 35)	5±30 4 (-41, 86)	-1±32 -4 (-95, 56)	-13±23 -12 (-69, 23)	
Paired t-test	0.02†	0.04	0.81	0.45	0.97†	0.04	

† When assumption of normality was violated, p-value was from Signed test.

Supplemental Data Table 1: Blood Pressure, Laboratory Tests, and Metabolic Indices Monitored During Study Therapy

Variable	Low Testosterone			High Testosterone			ANOVA P-value
	GH Placebo (n=19) Group A	GH 3ug (n=19) Group B	GH 5ug (n=20) Group C	GH Placebo (n=20) Group D	GH 3ug (n=17) Group E	GH 5ug (n=17) Group F	
HDL mg/dL							
Baseline	43±8	46±17	39±10	44±9	44±13	42±11	p=0.65
Week 16	48±8	50±20	42±10	46± 8	49±11	44±10	p=0.36
Change at Week 16	5 ±7 5 (-14, 18)	4±9 4 (-15, 22)	3±6 4 (-8, 12)	2±6 2 (-10, 15)	4±6 4 (-6, 12)	2±7 3 (-11, 15)	
Paired t-test	0.01	0.04	0.04	0.10	0.004	0.25	
LDL mg/dL							
Baseline	103±30	105±28	101±26	109±25	111±24	105±26	p=0.86
Week 16	114±34	114±26	100±26	117±30	112±27	100±27	p=0.30
Change at Week 16	11±22 10 (-57, 42)	9±20 6 (-29, 42)	-1±23 2 (-44, 47)	7±26 5 (-32, 75)	1±28 -2 (-68, 47)	-5±18 -4 (-56, 22)	
Paired t-test	0.01	0.06	0.87	0.21	0.94	0.24	